Effects of Topical Diclofenac on Tumor Metabolism

Neoplastic cells show an increased glucose metabolism and glycolysis which is associated with high lactate concentrations. There is also data for several tumor entities that high levels of lactate in the tumor are associated with tumor progression, metastasis and poor clinical outcome. Kreutz et al. demonstrated that diclofenac inhibits tumor cell proliferation in vitro and tumor growth in vivo via COX-independent effects on glucose metabolism. Diclofenac is taken up by tumor cells and inhibits tumor cell proliferation through inhibition of the oncogene MYC and subsequently glycolysis and block of lactate transport. MYC regulates genes involved in glycolysis and is upregulated in neoplastic cells, which is in line with the metabolic switch to glycolysis, the so called "Warburg effect", that cancer cells show. Although these results were found in vitro using human melanoma cells and in vivo in a mouse model, a similar mechanism of action is assumed to be relevant for the treatment of actinic keratoses with topical diclofenac. However tumor metabolism in diclofenac-treated actinic keratoses has never been investigated. To investigate the mechanism of action of diclofenac in the treatment of actinic keratoses, a clinical study analyzing particularly lactate levels, glycolysis and inflammatory infiltrate is needed.

Inclusion criteria

• Written informed consent has been signed prior to or at Screening Visit
• Caucasian male and female patients
• Age > 18 years
• Negative pregnancy test in women of childbearing age
• Clinical diagnosis of actinic keratosis (AK)
• A minimum of three AK lesions

Exclusion criteria

in immunocompromised patients :

• Concomitant UV-phototherapy
• Pregnancy or lactation
• Women in child-bearing age who do not use highly efficient contraceptive methods (<1% failure rate per year)
• Skin diseases that might interfere with response evaluation of study treatment
• Topical pretreatment of the AK study lesions with photodynamic therapy, Solaraze® 3% gel, Aldara®, 5-FU, or polyphenon E during the 8 weeks preceding study treatment
• Radiation therapy performed in the treatment area during the 3 months preceding study therapy
• Systemic treatment with diclofenac
• Known intolerance to diclofenac or to any other ingredient of Solaraze® 3% gel
• Conditions that might interfere with the ability to understand the study and thus give written informed consent
• Simultaneous participation in another clinical study or participation in another clinical study in the 30 days directly preceding inclusion
• Suspected lack of compliance

Exclusion criteria

in immunocompetent patients:

• Concomitant UV-phototherapy
• Pregnancy or lactation
• Women in child-bearing age who do not use highly efficient contraceptive methods (<1% failure rate per year)
• Patients with clinically relevant suppression of the immune system (e.g. drug induced, infection)
• Skin diseases that might interfere with response evaluation of study treatment
• Topical pretreatment of the AK study lesions with photodynamic therapy, Aldara®, Solaraze® 3% gel , 5-FU, or polyphenon E during the 8 weeks preceding study treatment
• Systemic treatment with cytostatic drugs or radiation therapy performed in the treatment area during the 3 months preceding study therapy
• Systemic treatment with diclofenac
• Known intolerance to diclofenac or to any other ingredient of Solaraze® 3% gel
• Conditions that might interfere with the ability to understand the study and thus give written informed consent
• Simultaneous participation in another clinical study or participation in another clinical study in participation in another clinical study in the 30 days directly preceding inclusion
• Suspected lack of compliance